July 22, 2025
A recent real-world study published in 2025 evaluated the clinical outcomes associated with early initiation of Xtandi (enzalutamide) therapy in metastatic castration-sensitive prostate cancer. The study demonstrated substantial clinical benefits, including improved survival rates and delayed disease progression, for patients who initiated Xtandi treatment earlier in their therapeutic regimen. These findings reinforce the clinical advantage of timely initiation of potent androgen receptor inhibitors, providing actionable insights to healthcare providers aiming to optimize therapeutic strategies for managing mCSPC effectively.
Citation: Clinical Oncology News, March 2025. Available at: https://www.clinicaloncologynews.com/xtandi-early-use-benefits-mcspc
Implication: Early initiation of Xtandi in mCSPC treatment may significantly enhance patient outcomes, influencing treatment sequencing guidelines.